As the largest integrated healthcare provider in the U.S., the VA presents tremendous opportunity for life sciences companies. This article provides actionable information about the VA's drug benefit design, drug pricing, clinical guidance, and formulary placement and management.
- When Consumer Protection, Unfair Trade Practices, And AI Collide
- Companies To Watch: Athira Pharma
- USPTO Proposed 'Terminal Disclaimer' Rule Could Impact Life Science Patent Protections
- Reading The Room In Oncology Drug Development
- Correct But Misleading: AI Hallucinations In Complex Decision-Making
- Patient Access Challenges Are Changing Pharma Investment Strategies
- Could GenAI Dramatically Reduce The Cost Of Regulatory Medical Writing?
- Cash Needed For Phase 3 Celiac Drug Development
COMPANIES TO WATCH
-
![Mark Litton]( "Companies To Watch: Athira Pharma")
Companies To Watch: Athira PharmaAthira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
![Charles Hugh-Jones]( "Companies To Watch: Volastra Therapeutics")
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
![Nicolas Poirier_OSE Immunotherapeutics]( "Companies To Watch: OSE Immunotherapeutics")
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
![Kristine Ball Headshot 2023]( "Companies To Watch: Antiva Biosciences")
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
WHERE ARE THEY NOW
-
![Otsuka cover_Oct 2016]( "Where Are They Now? Otsuka")
Where Are They Now? OtsukaOtsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
-
![Armon_Sharei_450x300]( "Where Are They Now? SQZ Biotech")
Where Are They Now? SQZ BiotechSQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
![WATN_Novo Nordisk]( "Where Are They Now? Novo Nordisk")
Where Are They Now? Novo NordiskIn a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
NEWSLETTER ARCHIVE
- Reading The Room In Oncology Drug Development
- Ten Years In, Project Data Sphere Is Snowballing
- Drug Discovery And Development, Powered By Physician Intelligence
- Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
- A Proactive Approach To 'Unscrupulous’ Patent Practices
SPOTLIGHT
Industry veteran James Sapirstein, CEO of Entero Therapeutics, discusses the company's lead candidate, a treatment for celiac disease, and makes the case for investors and Big Pharma to step up and help bring it across the finish line.
